MET-targeted therapies using repurposed inhibitors have met with some initial success in the clinic; however, unlike cancers driven by other oncogenes such as EGFR, response rates in METΔex14 mutant tumours are lower [20,21,22]. This evidence concerns the gene MET and cancer.